SCD Clinical Trials
We explore the controversy around whether sickle cell carriers are at a higher risk of developing health complications.
In countries such as the Democratic Republic of Congo, the fight against sickle cell disease takes up significant healthcare resources.
The COVID-19 pandemic has brought about a subsection of medical literature exploring the course of various diseases during the viral outbreak.
We review the most recent studies and guidelines on the management of pregnant women with sickle cell disease (SCD).
We examine the lasting impact of innovative clinical trial designs for rare diseases on other clinical experiments.
Two recently published studies detail the wide-reaching burden of sickle cell disease among patients of all ages.
L-glutamine was approved in 2017 to treat acute complications in patients with sickle cell disease, but uptake of and adherence to it have been limited.
Funding for sickle cell disease clinical trials and drug development has steadily increased and groundbreaking gene therapy research is being conducted.
Eliminating geographic and ethnic bias in clinical trials for rare diseases is the goal of Jeeva Informatics, says founder and CEO Harsha K. Rajasimha, PhD.
The Canadian Organization for Rare Disorders advocates for better diagnosis and drug access for Canada’s 3 million people with rare diseases.
When it comes to rare disorders, Israel—a New Jersey-sized nation of 9.3 million that’s made headlines this year for its highly successful coronavirus vaccination campaign—is clearly an emerging powerhouse.
Georgianne Arnold, MD, an expert on newborn screening, says the practice clearly saves lives, yet raises ethical concerns.